Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02171130 · ClinicalTrials.gov registry record · Phase 3
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 129
- Enrollment target
NCT02171130 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 129 participants.
The verdict
NCT02171130, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 129 participants
- Enrollment target
Study Summary
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of hypoglycemia. The population will be enriched to include participants who suffer from impaired hypoglycemia awareness.
Interventions
- DRUG Nasal Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02171130
The ClinicalTrials.gov registry entry for NCT02171130 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nasal Glucagon is the first listed.
NCT02171130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02171130 about?
NCT02171130 is a clinical study titled "Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia". Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of hypoglycemia. The population w...
What is the current status of trial NCT02171130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 2014-05. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02171130?
The interventions under investigation include: Nasal Glucagon (DRUG).
Who is sponsoring clinical trial NCT02171130?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.